evidence report efficacy safety mitoxantrone novantrone treatment multiple sclerosis abstract objective chemotherapeutic agent mitoxantrone approved multiple sclerosis ms num review evidence original report therapeutics technology assessment subcommittee num concluded mitoxantrone reduced clinical attack rates mri activity disease progression subsequent reports decreased systolic function heart failure leukemia prompted food drug administration institute black box warning num review undertaken examine literature efficacy safety mitoxantrone patients ms initial report methods relevant articles obtained review medical literature strength evidence graded american academy neurology evidence classification scheme results accumulated class iii iv evidence suggests increased incidence systolic dysfunction therapy-related acute leukemia tral mitoxantrone therapy systolic dysfunction occurs num patients ms treated mitoxantrone congestive heart failure occurs num leukemia occurs num number needed harm num systolic dysfunction num tral efficacy evidence change recommendation previous report conclusions risk systolic dysfunction leukemia patients treated mitoxantrone higher suggested time previous report comprehensive postmarketing surveillance data lacking glossary 
